Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Media

Press Releases - 2010

Newron: Data on Safinamide to Be Presented at the 14th MDS Meeting

10/06/2010
English ENG  German GER

Newron reports SERENA trial top-line results for ralfinamide

06/05/2010
English ENG  German GER

Shareholders approve all motions of the Board of Directors

06/04/2010
English ENG  German GER

Newron Pharmaceuticals reports 2009 results

03/03/2010
English ENG  German GER

Newron completes enrolment in SERENA Phase IIb/III study of Ralfinamide in patients with Neuropathic Low Back Pain

12/01/2010
English ENG  German GER

Newron Reports Positive Pre-IND Meeting with FDA and MHRA for its NCE NW-3509

11/01/2010
English ENG  German GER